Ethicon Suspends Minimally Invasive Uterine Surgery Equipment
While Ethicon's devices for the procedure have included a warning about the spread of cancerous cells, it has decided to suspend the devices until such time as the FDA clearly defines the risks associated with morcellation, according to the report.
"At Ethicon, our first priority is to our customers and patients," a company spokesman told the Enquirer.
More Articles on Quality:
5 Tips for Focusing Infection Control Policies
10 Things to Know About Infection Control
ASCA Encourages AHRQ ASC Patient Safety Program Participation
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- Is multimodal or patient-controlled analgesia more effective following an ACDF? 5 observations
- Stratifying risk — Using predictive analytics to pinpoint high-risk patients
- Coding productivity, accuracy decrease with start of ICD-10: 8 observations
- Global telemedicine market to grow at CAGR of 19%: 8 insights
- Obama administration rejects House $1.1B Zika bill: 4 things to know